Axsome Therapeutics, Inc. Balance Sheet
AXSM / Health Care|12 years of annual SEC 10-K data (FY2014-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 12 fiscal years. All figures from audited SEC 10-K filings.
Axsome Therapeutics, Inc. had $690M in total assets and $88M in shareholders' equity as of FY2025. Total debt was $118M against $323M in cash, resulting in a $205M net cash position.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $322.9M | $315.4M | $386.2M | $200.8M | $86.5M | $183.9M | $220.0M | - | - | - | - | - |
| Accounts Receivable | $224.5M | $142.0M | $94.8M | $37.7M | - | - | - | - | - | - | - | - |
| Inventory | $27.9M | $15.7M | $15.1M | $4.3M | - | - | - | - | - | - | - | - |
| Current Assets | $589.0M | $485.1M | $504.3M | $245.6M | $86.5M | $184.0M | $220.4M | $15.2M | $35.3M | $38.0M | $49.0M | - |
| PP&E (Net) | $562.0K | $584.0K | $846.0K | $722.0K | $283.8K | $52.6K | $30.6K | $51.8K | $68.1K | $100.7K | $16.7K | - |
| Goodwill | $12.0M | $12.0M | $12.0M | $10.3M | - | - | - | - | - | - | - | - |
| Total Assets | $689.8M | $568.5M | $588.2M | $331.5M | $87.8M | $186.1M | $220.5M | $15.4M | $35.6M | $38.2M | $49.1M | - |
| Current Liabilities | $378.8M | $230.1M | $138.9M | $96.6M | $23.1M | $23.4M | $24.5M | $10.8M | $12.2M | $7.2M | $2.6M | - |
| Total Debt | $117.7M | $180.7M | $178.1M | $94.3M | $49.1M | $48.3M | $17.3M | $3.6M | $6.7M | $9.5M | - | - |
| Shareholders' Equity | $88.3M | $57.0M | $191.0M | $109.6M | $15.6M | $113.8M | $178.7M | $937.9K | $16.7M | $21.6M | $46.4M | -$3.2M |